RU2627191C2 - Терапевтические собачьи иммуноглобулины и способы их применения - Google Patents

Терапевтические собачьи иммуноглобулины и способы их применения Download PDF

Info

Publication number
RU2627191C2
RU2627191C2 RU2013154302A RU2013154302A RU2627191C2 RU 2627191 C2 RU2627191 C2 RU 2627191C2 RU 2013154302 A RU2013154302 A RU 2013154302A RU 2013154302 A RU2013154302 A RU 2013154302A RU 2627191 C2 RU2627191 C2 RU 2627191C2
Authority
RU
Russia
Prior art keywords
antibody
heavy chain
fusion protein
seq
binding fragment
Prior art date
Application number
RU2013154302A
Other languages
English (en)
Russian (ru)
Other versions
RU2013154302A (ru
Inventor
Дэвид ГИРИНГ
Original Assignee
Нексвет Австралия Пти Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44838842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2627191(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нексвет Австралия Пти Лтд filed Critical Нексвет Австралия Пти Лтд
Publication of RU2013154302A publication Critical patent/RU2013154302A/ru
Application granted granted Critical
Publication of RU2627191C2 publication Critical patent/RU2627191C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
RU2013154302A 2011-05-06 2012-05-08 Терапевтические собачьи иммуноглобулины и способы их применения RU2627191C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161483481P 2011-05-06 2011-05-06
US61/483,481 2011-05-06
GBGB1114858.2A GB201114858D0 (en) 2011-08-29 2011-08-29 Anti-nerve growth factor antibodies and methods of using the same
GB1114858.2 2011-08-29
US201161531439P 2011-09-06 2011-09-06
US61/531,439 2011-09-06
PCT/GB2012/051008 WO2012153126A1 (en) 2011-05-06 2012-05-08 Therapeutic canine immunoglobulins and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2016102995A Division RU2626527C1 (ru) 2011-05-06 2012-05-08 Терапевтические собачьи иммуноглобулины и способы их применения

Publications (2)

Publication Number Publication Date
RU2013154302A RU2013154302A (ru) 2015-06-20
RU2627191C2 true RU2627191C2 (ru) 2017-08-03

Family

ID=44838842

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2013154302A RU2627191C2 (ru) 2011-05-06 2012-05-08 Терапевтические собачьи иммуноглобулины и способы их применения
RU2013154304A RU2644235C2 (ru) 2011-05-06 2012-05-08 Антитела против фактора роста нервов и способы их получения и применения
RU2016102995A RU2626527C1 (ru) 2011-05-06 2012-05-08 Терапевтические собачьи иммуноглобулины и способы их применения

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2013154304A RU2644235C2 (ru) 2011-05-06 2012-05-08 Антитела против фактора роста нервов и способы их получения и применения
RU2016102995A RU2626527C1 (ru) 2011-05-06 2012-05-08 Терапевтические собачьи иммуноглобулины и способы их применения

Country Status (18)

Country Link
US (1) US10040849B2 (enExample)
EP (3) EP2705057B8 (enExample)
JP (2) JP5990701B2 (enExample)
KR (4) KR101637502B1 (enExample)
CN (4) CN103732620B (enExample)
AU (2) AU2012252156B2 (enExample)
BR (2) BR112013028523A8 (enExample)
CA (3) CA2835092C (enExample)
DK (1) DK2705057T3 (enExample)
ES (2) ES2601400T3 (enExample)
GB (1) GB201114858D0 (enExample)
HU (1) HUE030654T2 (enExample)
MY (2) MY161724A (enExample)
PL (1) PL2705057T3 (enExample)
PT (1) PT2705057T (enExample)
RU (3) RU2627191C2 (enExample)
SG (5) SG194796A1 (enExample)
WO (2) WO2012153126A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818586C2 (ru) * 2019-07-15 2024-05-03 Интервет Интернэшнл Б.В. Антитела против собачьего ctla-4
US12435143B2 (en) 2019-07-15 2025-10-07 Intervet Inc. Caninized antibodies against canine CTLA-4

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
SI2270048T1 (sl) 2002-12-24 2016-01-29 Rinat Neuroscience Corp. Protitelesa proti NGF-ju in postopki uporabe le-teh
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
JP6622703B2 (ja) * 2013-12-20 2019-12-18 インターベット インターナショナル ベー． フェー． アンタゴニストの、抗イヌｐｄ−１抗体
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
WO2016156588A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
MA42138A (fr) * 2015-05-22 2018-03-28 Astellas Pharma Inc NOUVEAU FRAGMENT Fab D'ANTICORPS CONTRE LE NGF HUMAIN
CN108136007A (zh) * 2015-08-31 2018-06-08 宾夕法尼亚州大学信托人 用于治疗犬癌症的嵌合aav-抗vegf
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
FI3390451T3 (fi) 2015-12-18 2025-03-28 Intervet Int Bv Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan
WO2017119434A1 (ja) 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
CN108699141B (zh) * 2016-01-06 2022-06-17 定制药品研究株式会社 高亲和性抗vegf抗体
EA039434B1 (ru) * 2016-02-18 2022-01-27 Эланко Юэс Инк. Химерное собачье анти-cd20 антитело
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
CN113453716A (zh) * 2018-12-27 2021-09-28 金德雷德生物科学股份有限公司 兽用IgG Fc变体
JP2023513952A (ja) 2020-02-19 2023-04-04 アディボ ゲーエムベーハー 改変Ｆｃ領域
EP4114856A4 (en) * 2020-03-03 2023-11-22 Scout Bio, Inc. ANTIGEN BINDING MOLECULES AND THEIR USES
JP2023544839A (ja) * 2020-10-07 2023-10-25 ゾエティス・サービシーズ・エルエルシー 抗ｎｇｆ抗体及びその使用方法
AU2021366659A1 (en) * 2020-10-22 2023-06-08 Scout Bio, Inc. Method of suppressing immune response to vector-delivered therapeutic protein
KR20240006586A (ko) 2021-05-12 2024-01-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
WO2023034880A2 (en) 2021-08-31 2023-03-09 Scout Bio, Inc. Antigen-binding molecules and uses thereof
WO2024145278A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
FR3148027A1 (fr) * 2023-04-24 2024-10-25 Peptinov Composition vaccinale anti-ngf

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077332A2 (en) * 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
RU2367667C2 (ru) * 2004-08-19 2009-09-20 Дженентек, Инк. Полипептидные варианты с измененной эффекторной функцией

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
JP2837240B2 (ja) * 1990-06-07 1998-12-14 財団法人化学及血清療法研究所 イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
GB9202796D0 (en) 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
US7655231B2 (en) * 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
JP4263951B2 (ja) * 2003-06-20 2009-05-13 財団法人日本生物科学研究所 イヌ化抗体の作成方法および使用
JP2005104936A (ja) * 2003-10-01 2005-04-21 Nippon Zenyaku Kogyo Kk イヌｔａｒｃ抗体
JP2005143436A (ja) * 2003-11-18 2005-06-09 Nippon Zenyaku Kogyo Kk イヌｍｄｃ
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
SG152226A1 (en) * 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
WO2009016164A1 (en) * 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
WO2010110838A2 (en) * 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
WO2010117760A2 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
EP3333188B1 (en) * 2010-08-19 2022-02-09 Zoetis Belgium S.A. Anti-ngf antibodies and their use
US9289513B2 (en) 2011-03-23 2016-03-22 Option Pharmaceuticals, Llc Targeted cytokine for treatment of musculoskeletal diseases
MY161394A (en) 2011-05-06 2017-04-14 Nexvet Australia Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077332A2 (en) * 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
RU2367667C2 (ru) * 2004-08-19 2009-09-20 Дженентек, Инк. Полипептидные варианты с измененной эффекторной функцией

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRESTA et al., Engineering of therapeutic antibodies to minimize immunogenicity and optimize function, ADVANCED DRUG DELIVERY REVIEWS, 2006, vol.58, no.5-6, pp.640-656. TANG L. et al., Cloning and characterization of cDNAs encoding four different canine immunoglobulin γ chains, Veterinary Immunology and Immunopathology, 2001, Vol.80, Issues 3-4, pp.259-270. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818586C2 (ru) * 2019-07-15 2024-05-03 Интервет Интернэшнл Б.В. Антитела против собачьего ctla-4
US12435143B2 (en) 2019-07-15 2025-10-07 Intervet Inc. Caninized antibodies against canine CTLA-4

Also Published As

Publication number Publication date
AU2012252151A1 (en) 2013-11-14
SG194794A1 (en) 2013-12-30
CN105999261A (zh) 2016-10-12
EP2705057B1 (en) 2016-08-03
SG10201500960TA (en) 2015-04-29
KR20160079939A (ko) 2016-07-06
NZ617450A (en) 2015-01-30
MY161295A (en) 2017-04-15
BR112013028523A8 (pt) 2017-12-19
WO2012153126A1 (en) 2012-11-15
EP2705054B1 (en) 2018-11-14
EP2705054A1 (en) 2014-03-12
RU2013154302A (ru) 2015-06-20
ES2704036T3 (es) 2019-03-13
JP5990701B2 (ja) 2016-09-14
CN103732620B (zh) 2017-02-22
PL2705057T3 (pl) 2017-08-31
CN103732622A (zh) 2014-04-16
RU2644235C2 (ru) 2018-02-08
CA2906505A1 (en) 2012-11-15
KR20170070271A (ko) 2017-06-21
CA2834992C (en) 2016-07-26
DK2705057T3 (en) 2016-11-28
SG194796A1 (en) 2013-12-30
AU2012252156B2 (en) 2015-11-12
CA2834992A1 (en) 2012-11-15
NZ617446A (en) 2014-12-24
HUE030654T2 (en) 2017-05-29
GB201114858D0 (en) 2011-10-12
EP3502137A1 (en) 2019-06-26
AU2012252151B2 (en) 2016-08-04
SG10201607259TA (en) 2016-10-28
CN105833268A (zh) 2016-08-10
JP2014522236A (ja) 2014-09-04
EP2705057B8 (en) 2016-09-21
MY161724A (en) 2017-05-15
CA2835092A1 (en) 2012-11-15
KR20140056182A (ko) 2014-05-09
ES2601400T3 (es) 2017-02-15
CA2906505C (en) 2016-07-19
JP2014516026A (ja) 2014-07-07
US10040849B2 (en) 2018-08-07
CN103732620A (zh) 2014-04-16
BR112013028654A2 (pt) 2016-11-29
KR101783398B1 (ko) 2017-10-10
KR101637502B1 (ko) 2016-07-08
RU2013154304A (ru) 2015-06-20
CA2835092C (en) 2020-12-08
BR112013028523A2 (pt) 2016-11-29
SG10201500954WA (en) 2015-04-29
RU2626527C1 (ru) 2017-07-28
EP2705057A1 (en) 2014-03-12
KR20140041533A (ko) 2014-04-04
PT2705057T (pt) 2016-11-09
US20150017154A1 (en) 2015-01-15
WO2012153121A1 (en) 2012-11-15
AU2012252156A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
RU2627191C2 (ru) Терапевтические собачьи иммуноглобулины и способы их применения
JP5969102B2 (ja) 治療用イヌ免疫グロブリンおよびそれを用いる方法
JP6526089B2 (ja) 抗神経成長因子抗体ならびにそれを調製および使用する方法
CN103732621B (zh) 抗神经生长因子抗体及其制备和使用方法
AU2024205477A1 (en) Anti-BCMA heavy chain-only antibodies
US20230312738A1 (en) System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
US20140294815A1 (en) Caninised tumour necrosis factor antibodies and methods of using the same
NZ617450B2 (en) Therapeutic canine immunoglobulins and methods of using the same
HK1195572B (en) Therapeutic canine immunoglobulins and methods of using the same
NZ621619B2 (en) Caninised tumour necrosis factor antibodies and methods of using the same

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant